Menopause & Your
Glaucoma Risk

Estrogen is far more than a reproductive hormone. It plays a critical role in maintaining the health and function of multiple structures within the eye. Three types of estrogen receptors — ERα, ERβ, and GPR30 — have been identified throughout the eye, including the retina, trabecular meshwork, Schlemm’s canal, ciliary body, and cornea. Immunohistochemistry has specifically confirmed ERα expression in human trabecular meshwork and Schlemm’s canal outflow tissue (Youngblood H et al., Exp Eye Res 2023).

The protective mechanisms of estrogen on the eye include:

• Regulating aqueous humor outflow: Estrogen signaling promotes IOP homeostasis through multiple pathways: extracellular matrix turnover, nitric oxide production, focal adhesion assembly, mechanosensation, and actin stress fiber modulation within the trabecular meshwork. When estrogen levels are adequate, the drainage system functions more efficiently, helping maintain healthy IOP.
• Promoting blood flow to the optic nerve: Estrogen supports vasodilation through nitric oxide pathways, improving blood supply to the optic nerve head. Adequate perfusion is essential for keeping retinal ganglion cells alive and functional.
• Reducing oxidative stress: Estrogen acts as an antioxidant, scavenging free radicals that can damage cells in the retina and optic nerve. This is particularly important because the retina has one of the highest oxygen consumption rates of any tissue in the body.
• Protecting retinal ganglion cells from apoptosis: RGCs express estrogen receptors, and estrogen has been shown to directly inhibit programmed cell death (apoptosis) and activate protective signaling pathways in these cells. In a mouse model of inherited glaucoma, 17β-estradiol eye drops preserved retinal ganglion cells and maintained visual function even in the presence of elevated IOP (Prokai-Tatrai K et al., Mol Pharmaceutics 2013).

This biology is directly relevant to treatment. Selective Laser Trabeculoplasty (SLT) and minimally invasive glaucoma surgery (MIGS) procedures such as iStent® implantation and goniotomy target the same trabecular meshwork structures that are compromised by estrogen loss. Understanding this connection helps our surgeons tailor treatment timing and approach, particularly for women in the menopausal transition.

When estrogen levels decline during menopause, all of these protective pathways are weakened, creating a window of vulnerability for the development or progression of glaucoma.

Multiple large-scale epidemiological studies have established a connection between menopause and increased glaucoma risk. The evidence is compelling and spans several dimensions:

Intraocular Pressure Changes: Postmenopausal women have an IOP 1.5 to 3.5 mmHg higher than age-matched premenopausal women. In animal models, surgical menopause (ovariectomy) reduced aqueous humor outflow facility by as much as 34%, directly contributing to elevated IOP (Feola AJ et al., IOVS 2020).

Early Menopause as a Risk Multiplier: The Rotterdam Study found that women with menopause before age 45 had a 2.6-fold increased risk of open-angle glaucoma compared to those reaching menopause after age 50 (Hulsman CA et al., Am J Epidemiol 2001). A dose–response pattern has been observed: the earlier the menopause, the higher the glaucoma risk — mirroring the relationship seen in cardiovascular disease.

Surgical Menopause: Women who underwent bilateral oophorectomy before natural menopause were at increased risk of developing glaucoma later in life. Preclinical studies show that the abrupt estrogen loss from oophorectomy causes greater retinal ganglion cell loss and visual dysfunction after optic nerve injury than natural aging alone.

Sex as an Overlooked Risk Factor: High IOP in women can emerge an entire decade earlier than in men (ages 51–60 vs. 61–70), a window that corresponds with the average age of menopause onset (51 years). Despite this, sex is not currently classified as a formal risk factor for glaucoma, and most clinical guidelines do not account for menopausal status.

While these findings are compelling, it is important to note that glaucoma is a multifactorial disease. Menopause is one risk factor among many, and not all postmenopausal women will develop glaucoma. However, the evidence strongly supports the value of proactive screening for women during and after the menopausal transition.

The relationship between hormone replacement therapy (HRT) and glaucoma is one of the most active areas of ophthalmic research. Recent large-scale studies have produced specific, quantifiable findings.

IOP Reduction: A 2025 systematic review and meta-analysis of 9 studies with 1,024 participants found HRT was associated with a significant IOP reduction of 3.84 mmHg (95% CI: 2.26–5.41, p < 0.01) using a random-effects model (Safarpour Lima B et al., Eur J Transl Myol 2025).

Dose-Dependent Delay in Glaucoma Onset: A 2024 study of 2,952 female veterans with open-angle glaucoma found that HRT use was associated with a dose-dependent delay in glaucoma diagnosis (Hogan K et al., IOVS 2024):

• 0–2 years of HRT → 2.20-year delay in diagnosis
• 2–5 years of HRT → 3.74-year delay in diagnosis
• >5 years of HRT → 4.51-year delay in diagnosis

Each additional prescription-year of HRT was associated with a 0.18-year later age of glaucoma diagnosis. The protective effect was greatest in women who experienced early menopause (3.6-year delay) and smallest in those with late menopause (2.7-year delay).

Estrogen-Only vs. Combination HRT: Analysis of the Women’s Health Initiative (WHI) dataset found that estrogen-only HRT reduced glaucoma risk in women of African American descent, but combination estrogen + progesterone HRT did not show the same benefit. A JAMA Ophthalmology study of >152,000 women found a 0.4% reduced risk of developing POAG for each additional month of estrogen-only postmenopausal hormone use (Newman-Casey PA et al., JAMA Ophthalmol 2014).

Racial Differences in HRT Response: HRT use trended toward a greater delay in glaucoma diagnosis in Black women compared to White women (e.g., >5 years HRT: 4.80-year delay vs. 4.08-year delay), though this difference was not statistically significant in available data.

Important Clinical Caveat: HRT carries known systemic risks (cardiovascular events, breast cancer with long-term combined HRT) and is not currently recommended solely for glaucoma prevention. The decision to use HRT should be made with your gynecologist or primary care provider based on your overall health profile. More prospective, randomized studies are needed before clinical guidelines can be established. If you are already on HRT, it is important to inform your eye doctor, as this information is relevant to your glaucoma risk assessment.

Regardless of HRT status, regular comprehensive eye exams with glaucoma-specific testing remain the most reliable way to protect your vision during and after menopause.

Glaucoma is not the only eye condition affected by the hormonal changes of menopause. The decline in estrogen, progesterone, and androgens influences multiple ocular structures and can contribute to or worsen several conditions:

• Dry eye syndrome: Affecting up to 61% of perimenopausal and menopausal women, this is the most common eye complaint during menopause. Estrogen and androgen decline impair meibomian and lacrimal gland function, reducing tear production and destabilizing the tear film, leading to irritation, burning, fluctuating vision, and increased sensitivity.
• Refractive shifts: Estrogen decline can alter corneal thickness and curvature, potentially affecting your glasses or contact lens prescription.
• Optic nerve head perfusion changes: Statistical differences in ocular blood flow between men and women disappear after menopause, suggesting that estrogen plays a role in maintaining healthy optic nerve perfusion in premenopausal women.

These conditions are why comprehensive eye care during and after menopause is so important. At Greenwich Ophthalmology Associates, we evaluate the full picture of your eye health — not just one condition in isolation.

While you cannot control hormonal changes, there are meaningful steps you can take to lower your risk and protect your vision:

• Schedule annual comprehensive eye exams: This is the single most important step. Glaucoma testing should include IOP measurement, optic nerve evaluation, OCT imaging, and visual field testing. Beginning at age 40, all women should have a baseline glaucoma screening, and exams should become annual during and after menopause.
• Know your family history: If a parent or sibling has glaucoma, your risk is significantly higher. Share this information with your eye doctor so that monitoring can begin earlier and be more thorough.
• Exercise regularly: Moderate aerobic exercise (walking, swimming, cycling) has been shown to lower IOP and improve blood flow to the optic nerve. Aim for 30 minutes of moderate activity most days of the week. Avoid heavy weight lifting and inverted yoga poses, which can temporarily spike IOP.
• Maintain a healthy diet: Leafy green vegetables, omega-3 fatty acids (from fish, flaxseed, and walnuts), and antioxidant-rich fruits and vegetables support overall eye health. Some research suggests that nitrate-rich vegetables like spinach and kale may help maintain healthy IOP.
• Manage systemic health conditions: Diabetes, high blood pressure, and cardiovascular disease can all worsen glaucoma. Work with your primary care provider to keep these conditions well controlled.
• Avoid smoking: Smoking increases oxidative stress and reduces blood flow to the optic nerve, compounding the effects of estrogen decline.
• Coordinate care between your providers: If you are seeing a gynecologist for menopausal symptoms, make sure your eye doctor is aware of any hormonal treatments you are receiving. This integrated approach ensures that all aspects of your health are considered.

Understanding the clinical timeline of menopause helps clarify when glaucoma risk begins to change:

• Perimenopause typically begins in a woman’s 40s and is marked by irregular cycling, declining ovarian hormone output, and vasomotor symptoms (hot flashes, night sweats).
• Menopause is confirmed after 12 contiguous months of amenorrhea, with the average onset at age 51.
• Premature and early menopause affects approximately 10% of women. Premature menopause occurs before age 40; early menopause occurs between ages 40 and 45, according to InterLACE consortium data.
• Surgical menopause (bilateral oophorectomy) causes an abrupt and complete loss of ovarian estrogen, distinct from the gradual decline in natural menopause. This sudden drop carries its own set of risk implications for the eyes.

The distinction between natural and surgical menopause matters for glaucoma risk assessment. Abrupt estrogen loss is associated with greater retinal ganglion cell loss and visual dysfunction compared to the gradual decline seen in natural menopause.

Research has identified menopause-related associations across multiple forms of glaucoma:

• Primary Open-Angle Glaucoma (POAG): The strongest evidence exists here. Early menopause doubles risk, and HRT delays onset. The trabecular meshwork dysfunction caused by estrogen loss directly contributes to elevated IOP in POAG.
• Primary Angle-Closure Glaucoma (PACG): Several population studies find women more at risk post-menopause. Women using postmenopausal hormones have been shown to have less angle closure.
• Exfoliation Glaucoma (XFG): Interestingly, greater lifetime estrogen exposure (younger menarche, longer oral contraceptive use, surgical menopause) has been associated with higher XFG risk — a paradox that researchers believe involves different biological pathways than the protective effects seen in POAG.

Understanding which type of glaucoma is present helps Dr. Shields and Dr. Shakarov determine the most appropriate treatment approach for each patient.

Research reveals important disparities in how menopause-related glaucoma affects different populations:

• Earlier onset: Women of Black or African American descent develop glaucoma at a significantly earlier age than White women, even after accounting for menopause age, BMI, blood pressure, and comorbidities.
• HRT response differences: HRT use trended toward a greater delay in glaucoma diagnosis in Black women compared to White women. For women using HRT for more than 5 years, Black women saw a 4.80-year delay in diagnosis compared to a 4.08-year delay for White women, though this difference was not statistically significant in current data.
• Estrogen-only HRT benefit: The Women’s Health Initiative trial found that estrogen-only HRT reduced glaucoma risk specifically in African American women, while combination estrogen + progesterone HRT did not show the same benefit in this population.

These disparities underscore the importance of individualized risk assessment and proactive screening for all women, with particular attention to women of African American descent who may face compounded risk factors.

The evidence linking menopause and glaucoma informs every aspect of how Dr. Shields and Dr. Shakarov evaluate and treat their patients. Our surgeons are trained in every tier of glaucoma management:

• Personalized Risk Assessment: When a patient presents for a glaucoma evaluation, our specialists incorporate menopausal history — including age of onset, whether menopause was natural or surgical, and any history of HRT — alongside traditional risk factors such as family history, IOP, and ethnicity.
• Selective Laser Trabeculoplasty (SLT): A safe, in-office laser procedure that improves aqueous outflow through the trabecular meshwork. SLT is particularly relevant for patients whose trabecular meshwork function may be compromised by estrogen decline, as it directly targets the same structures affected by hormonal changes.
• Minimally Invasive Glaucoma Surgery (MIGS): Dr. Shields and Dr. Shakarov perform iStent® implantation and goniotomy, often combined with cataract surgery. These procedures offer meaningful IOP reduction with a favorable safety profile, making them an excellent option for women with early to moderate glaucoma who want to reduce their dependence on daily eye drops.
• Combined Cataract–Glaucoma Surgery: For patients who need both cataract removal and glaucoma intervention, our surgeons perform both in a single session using laser-assisted cataract surgery with premium intraocular lens implantation alongside a MIGS procedure, minimizing recovery time and optimizing visual outcomes.
• Incisional Glaucoma Surgery: For advanced or refractory cases requiring more aggressive IOP lowering, Dr. Shields and Dr. Shakarov perform trabeculectomy and tube shunt surgery. Their fellowship training at Johns Hopkins Wilmer Eye Institute and Weill Cornell Medical College ensures that even complex surgical cases receive expert-level care.

We welcome referrals from OB/GYNs, primary care physicians, endocrinologists, and optometrists. If your patient is perimenopausal or postmenopausal and has additional glaucoma risk factors, we encourage a comprehensive glaucoma evaluation.

The American Academy of Ophthalmology (AAO) recommends the following intervals for comprehensive eye exams:

• Ages 40–54: Every 2–4 years
• Ages 55–64: Every 1–3 years
• Ages 65+: Every 1–2 years

However, women with early menopause (before 45) or surgical menopause should be considered for earlier and more frequent comprehensive eye exams at the more frequent end of these intervals. These exams should include IOP measurement, optic nerve evaluation, OCT imaging, and visual field testing.

Clinicians should ask about menopausal history (age of onset, natural vs. surgical, HRT use) as part of a thorough glaucoma risk assessment. Referring physicians — OB/GYNs, primary care providers, and endocrinologists — should be aware that menopause may increase glaucoma risk and consider ophthalmic referral for women with additional risk factors (family history, African descent, elevated IOP).

Genetic studies have provided molecular evidence for why estrogen matters in glaucoma:

• A panel of SNPs (single nucleotide polymorphisms) in 23 estrogen metabolic and signaling pathway genes — including ESR1, ESR2, CYP1B1, and COMT — was significantly associated with primary open-angle glaucoma in females but not in males.
• Variants in CAV1/CAV2 — genes involved in estrogen receptor signaling — show POAG association predominantly in women.
• Variants in NOS3 (nitric oxide synthase, which interacts with ERα signaling) are associated with POAG only in women.
• In animal models, loss of aromatase (the enzyme that converts androgens to estradiol) causes elevated IOP and retinal ganglion cell loss in female mice by just 12 weeks of age.

These findings provide a molecular basis for the clinical observations linking estrogen decline to increased glaucoma risk in women, and may eventually lead to more targeted screening and treatment approaches.

Several promising avenues of research may shape the future of glaucoma care for women:

• Topical estrogen therapy: 17β-estradiol eye drops have shown significant neuroprotective effects in preclinical models without systemic exposure, but human clinical trials are needed before this can become a treatment option.
• Targeted estrogen receptor modulators (SERMs): Selective agonists for ERα, ERβ, or GPR30 could offer IOP-lowering and neuroprotective benefits while minimizing systemic hormone risks.
• Prospective clinical trials: No randomized controlled trial has yet tested HRT specifically for glaucoma prevention. Researchers have called for prospective studies with IOP and visual function endpoints.
• Transcriptomic profiling: Recent work shows that surgical menopause alters immune, metabolic, and transcription factor pathways in ocular tissue, offering potential therapeutic targets for future treatments.

While these developments are still in the research pipeline, they underscore the growing recognition that hormonal factors play a meaningful role in glaucoma and deserve dedicated clinical attention.